X

pharmaceuticals

AbbVie (ABBV) Earnings: 4Q20 Key Numbers

AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today. Worldwide net revenues rose 59.2% year-over-year to $13.8 billion…

Pfizer (PFE) Q4 Earnings: Key financials and quarterly highlights

Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2020 earnings results today. Revenues increased 12% year-over-year to $11.7 billion. On…

Infographic: Vertex Pharmaceuticals (VRTX) 4Q20 Earnings Results

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported fourth quarter 2020 earnings results today. Total revenues increased 15% year-over-year to $1.62 billion.…

Where do these companies stand in the COVID-19 vaccine race?

After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19…

Johnson & Johnson’s (JNJ) single-dose vaccine is effective but lags behind rivals

Johnson & Johnson (NYSE: JNJ) is the latest pharma company to provide results from the trial of its COVID-19 vaccine candidate.…

Fate Therapeutics (FATE) looks headed for a turnaround post-COVID

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from…

Johnson & Johnson (JNJ): Strength in ecommerce drives growth in Consumer Health

Shares of Johnson & Johnson (NYSE: JNJ) gained nearly 3% in morning trade on Tuesday after the company reported fourth…

Johnson & Johnson (JNJ) beats market estimates in Q4

Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2020 financial results before the regular market hours on Tuesday. The pharmaceutical giant…

Merck (MRK) pulls out of the COVID-19 vaccine race; will focus on investigational therapeutic candidates

Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical…

COVID-related medical costs may weigh on UnitedHealth’s performance this year

The health insurance sector has been facing multiple challenges from the virus crisis, but market-leading healthcare firm UnitedHealth Group (NYSE:…

Latest study shows Eli Lilly’s (LLY) antibody reduces COVID-19 by 80%

Eli Lilly and Company (NYSE: LLY) announced that the results from its latest study indicated that its monoclonal antibody bamlanivimab…

Codexis (CDXS) may be moving closer to profitability, after beating slowdown

Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its…

Covid vaccine won’t dent Ampio Pharma’s market: CEO Michael Macaluso

Since its foundation in 2008, Ampio Pharmaceuticals (NYSE: AMPE) has been focused on delivering a drug that treats inflammation caused…

Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch

Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the…

Rite Aid (RAD) looks to regain lost ground with new rebound strategy

Rite Aid Corporation (NYSE: RAD) is on a mission to put the house in order and achieve sustainable profitability, after…

Trxade Group Inc. (NASDAQ: MEDS) Q4 2020 Research Summary

Ticker MEDSExchange NASDAQFounded 2013Headquarters FloridaIndustry TechnologyMarket Cap $45 million Trxade Group Inc (NASDAQ: MEDS) has been serving pharmacies and drug…

COVID vaccine: Single-dose regimen can give Johnson & Johnson (JNJ) an edge

Johnson & Johnson (NYSE: JNJ) has adopted a slow and steady approach in its COVID vaccine research, which is one…

Rite Aid Corporation (RAD) Q3 2021 Earnings Call Transcript

Rite Aid Corporation (NYSE: RAD) Q3 2021 earnings call dated Dec. 17, 2020. Corporate Participants: Trent Kruse -- Senior Vice President, Investor…

Infographic: Highlights of Rite Aid’s (RAD) Q3 2021 earnings report

Rite Aid Corporation (NYSE: RAD) reported a decline in third-quarter earnings, despite an increase in revenues, as margins were hurt…

Alexion’s long-term prospects remain intact amid continued focus on rare diseases

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has stood out in the crowded pharmaceuticals marketplace by developing effective treatments for certain rare health…

Is it the right time to invest in Agilent Technologies (A)?

Agilent Technologies, Inc. (NYSE: A) ended fiscal 2020 on a positive note, bettering its performance consistently after experiencing a slowdown…